Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02635269
Other study ID # Metabolic Myopathy
Secondary ID H-15015150
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date January 2016
Est. completion date December 2020

Study information

Verified date October 2019
Source Rigshospitalet, Denmark
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to characterize the pathophysiological mechanisms of 21 different metabolic myopathies. The study will focus on exercise capacity and the metabolic derangement during exercise.


Description:

Patients will be compared to a group of matched healthy control subjects (matched for age, gender, physical activity level and BMI) for comparison of the primary and secondary outcome measures.

Methods:

Each subject will go through 3 test days.

Test day 1:

- International Physical Activity Questionnaire (IPAQ). The results will be used to match the patients to control subjects.

- DEXA-scan. This is used to estimate the volume of distribution for stable isotope tracers.

- Maximal oxidative capacity test (max-test). On a cycle ergometer, subjects will exercise for approximately 15 minutes with increasing resistance until exhaustion. The peak oxidative and workload capacities will be compared to the healthy controls and will be used to find the workload that corresponds to 55-65 % of VO2max used in the following exercise tests.

- Blood samples. Samples will be drawn before exercise and at exhaustion and will be analyzed for the plasma concentrations of glucose, lactate, ammonia, creatine kinase and myoglobin.

Test day 2:

•Long exercise test #1. The purpose of this test is to measure the total fat and sugar oxidation rates during exercise by using stable isotope tracers.

Subjects arrive at the laboratory after 3-9 hours of fasting. One IV-catheter is inserted in the cubital vein in one arm and another in a peripheral vein in the other hand. The stable isotope tracers will be given in the cubital vein as a constant infusion of solutions of:

- [U-13C]-palmitate (0.0026 mg x kg-1 x min-1, after a priming bolus of 0.085 mg x kg-1 NaH13CO3)

- [1,1,2,3,3-2H5]-glycerol (0.0049 mg x kg-1 x min-1 )

- [6.6-2H2]-glucose (0.0728 mg x kg-1 x min-1 ) For two hours the subjects rests while receiving the infusions until the tracers have distributed in the body and reached a steady state. After the rest, the subjects exercise on the cycle-ergometer until exhaustion or for a maximum of 1 hour at an intensity that corresponds to 55-65% of VO2max.

The heart rate is continuously measured during exercise, and every other minute the subject evaluates his/her degree of exertion (Rate of Perceived Exertion, RPE) on a Borg scale.

•Blood and breath samples From 20 minutes before exercise and every ten minutes until the end of exercise, blood samples are drawn and samples of the expired breath are collected.The breath is analysed for 13CO2 -enrichment. The blood is analysed for the plasma concentrations of glucose, lactate, ammonia, creatine kinase and myoglobin.

Test day 3:

•Long exercise test #2. The purpose of this test is to investigate exercise capacity and performance measured as HR, VO2 and RPE during prolonged exercise. To mimic the conditions for the working muscles in healthy persons who have an intact metabolism, the patients are given an infusion of a 10% glucose solution to maintain the blood sugar while exercising.

Subjects arrive at the laboratory after 3-9 hours fasting. After 2 hours of rest, the subjects exercise on the cycle-ergometer until exhaustion or for a maximum of 1 hour at an intensity that corresponds to 60-65% of VO2max, like they did on test day 2. This time the subjects are not given stable isotope tracers. 10 minutes before exercising, the subjects are given a bolus of glucose solution 0.2 g/kg in a cubital vein catheter and a constant infusion of 10% glucose solution is started (100ml/h). The infusion continues throughout the exercise period.

Assessments of heart rate, Rate of Perceived Exertion and blood sampling follow the same protocol as on test day 1, except no breath samples are taken and no analyses of stable isotopes are made, since the tracers are not used on test day 3.

- Blood samples. From 20 minutes before exercise and every ten minutes until the end of exercise, blood samples are drawn. The blood is analysed for the plasma concentrations of glucose, lactate, ammonia, creatine kinase and myoglobin.

- Muscle Biopsy At the end of test day 1 the investigators will perform a voluntary muscle biopsy.

Statistical Methods:

The investigators will use a paired t-test, two-tailed testing (or the corresponding non-parametric test, if the assumption of normality is not met). A p-value of < 0.05 will be considered significant. Results will be reported with Confidence Intervals of the difference in means. SigmaPlot version 11.0 (or a similar statistical program) will be used for statistical analysis.

No interim analyses will be made during the 4 days trial period. In the case, that a patient withdraws/is withdrawn, the obtained data from the completed tests will be included in the analyses. Raw data that is clearly and indisputably a result of an error in measurement will not be included (evaluated by the investigator). Missing or lost data will if possible be reassessed.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 60
Est. completion date December 2020
Est. primary completion date August 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 15 Years to 80 Years
Eligibility Inclusion Criteria:

- Men and women with genetically and/or biochemically verified LCHAD Deficiency

- Healthy controls needs to be healthy to be included, evaluated by the investigator.

Exclusion Criteria:

- Competing conditions at risk of compromising the results of the study.

- Pregnancy or breastfeeding

- Cardiac or pulmonary disease contraindicating peak exercise testing or strenuous exercise.

- Inability to understand the purpose of the trial or corporate for the conduction of the experiments.

- Veins that are too difficult to puncture for blood sampling or insertion of intravenous catheters, evaluated by the investigator

- Moderate to severe muscle weakness, that prevents the subject completing 10 minutes of cycle-ergometry exercise at 60-70 % of VO2peak, evaluated by the investigator.

- Participation in other trials that may interfere with the results.

- Intake of medications that may interfere with the results or may compromise exercise performance, as evaluated by the investigators.

- Donation of blood within 30 days prior to conduction of the tests on test day 1.

Study Design


Related Conditions & MeSH terms

  • Beta Enolase Deficiency
  • Carbohydrate Metabolism, Inborn Errors
  • Carnitine Palmitoyl Transferase 2 Deficiency
  • Carnitine Transporter Deficiency
  • Glycogen Storage Disease
  • Glycogen Storage Disease Type II
  • Glycogen Storage Disease Type III
  • Glycogen Storage Disease Type IV
  • Glycogen Storage Disease Type V
  • Glycogen Storage Disease Type VII
  • Glycogen Synthase Deficiency
  • Glycogenin-1 Deficiency (Glycogen Storage Disease Type XV)
  • Lactate Dehydrogenase Deficiency
  • Lipid Metabolism, Inborn Errors
  • Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency
  • Medium-chain Acyl-CoA Dehydrogenase Deficiency
  • Metabolic Diseases
  • Metabolism, Inborn Errors
  • Multiple Acyl-CoA Dehydrogenase Deficiency
  • Muscle Phosphofructokinase Deficiency
  • Neutral Lipid Storage Disease
  • Phosphoglucomutase 1 Deficiency
  • Phosphoglycerate Kinase Deficiency
  • Phosphoglycerate Mutase Deficiency
  • Phosphorylase Kinase Deficiency
  • VLCAD Deficiency

Intervention

Other:
Sugar
10 minutes before exercising, the subjects are given a bolus of glucose solution 0.2 g/kg in a cubital vein catheter and a constant infusion of 10% glucose solution is started (100ml/h). The infusion continues throughout the exercise period.

Locations

Country Name City State
Denmark Neuromuscular Research Unit, 3342 Copenhagen

Sponsors (1)

Lead Sponsor Collaborator
Rigshospitalet, Denmark

Country where clinical trial is conducted

Denmark, 

References & Publications (3)

Liang WC, Nishino I. State of the art in muscle lipid diseases. Acta Myol. 2010 Oct;29(2):351-6. Review. — View Citation

Oldfors A, DiMauro S. New insights in the field of muscle glycogenoses. Curr Opin Neurol. 2013 Oct;26(5):544-53. doi: 10.1097/WCO.0b013e328364dbdc. Review. — View Citation

Ørngreen MC, Dunø M, Ejstrup R, Christensen E, Schwartz M, Sacchetti M, Vissing J. Fuel utilization in subjects with carnitine palmitoyltransferase 2 gene mutations. Ann Neurol. 2005 Jan;57(1):60-6. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Total fat oxidation (rate of disappearance) during prolonged moderate intensity exercise. Measured as micro mol per kg per minute. Measured using stable isotope technique ([U-13C]-palmitate, [1,1,2,3,3-2H5]-glycerol and [6.6-2H2]-glucose ) and indirect calorimetry. Measured at at time (minutes) -120, -20, -10, 0, 10, 20, 30, 40, 50, 60. Zero is the indicatet start of 1 hour cycling test. Measured on day 2 of participation
Secondary Maximal oxidative capacity (mL*kg-1*minutes-1) Oxidative capacity is measured continuously during a maximum exercise test on the first day of the trial. The test lasts about 15 minutes (when the participant is fully exhausted). The maximal oxidative capacity is the peak measure during the test. Day 1 of participation
Secondary Endurance measured as minutes:seconds During 1 hour cycling test 1 and 1 hour cycling test 2 on day 2 and 4 of participation. The test will last for 1 hour or until exhaustion. Endurance will be defined as the total exercise duration. Day 2 and 4 of participation
Secondary Heart rate (HR) during prolonged exercise, with and without blood sugar maintained by an infusion of a 10% glucose solution. Measured in beats per minute. During 1 hour cycling at 55-65% of VO2max the heart rate is measured every 2 minuts. During 1 hour cycling test 1 and 1 hour cycling test 2 on day 2 and 4 of participation.
Secondary Oxygen consumption rate (VO2) during prolonged exercise, with and without blood sugar maintained by an infusion of a 10% glucose solution. Measured in mL. During 1 hour cycling at 55-65% of VO2max the oxygen consumption rate is continuously measured. During 1 hour cycling test 1 and 1 hour cycling test 2 on day 2 and 4 of participation.
Secondary Self-evaluated exertion (Rate of Perceived Exertion (RPE)) during prolonged exercise, with and without blood sugar maintained by an infusion of a 10% glucose solution. Measured using a Borg-scale (6-20). During 1 hour cycling at 55-65% of VO2max the participant is asked to rate their exertion every 2 minutes. During 1 hour cycling test 1 and 1 hour cycling test 2 on day 2 and 4 of participation.
Secondary Maximal workload capacity. Measured in watt The participant will be cycling at incremental workload until exhaustion. The test lasts about 15 minutes (when the participant is fully exhausted). The maximal workload is the peak measure at the end of the test. Day 1 of participation
Secondary Total glucose oxidation (rate of disappearance) during prolonged moderate intensity exercise. Measured as micro mol per kg per minute. Measured using stable isotope technique ([U-13C]-palmitate, [1,1,2,3,3-2H5]-glycerol and [6.6-2H2]-glucose ) and indirect calorimetry. Measured at at time (minutes) -120, -20, -10, 0, 10, 20, 30, 40, 50, 60. Zero is the indicatet start of 1 hour cycling test. Measured on day 2 of participation
See also
  Status Clinical Trial Phase
Recruiting NCT00231400 - Pompe Disease Registry Protocol
Recruiting NCT04910776 - Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa Phase 3
Not yet recruiting NCT05017402 - Higher Dose of Alglucosidase Alpha for Pompe Disease
Withdrawn NCT01656590 - High Protein and Exercise Therapy Plus Nocturnal Enteral Feeding in Juvenile-onset Pompe Disease Phase 2
Completed NCT00701129 - An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naive Cross-Reacting Immunologic Material (CRIM[-]) Patients With Infantile-Onset Pompe Disease Phase 4
Active, not recruiting NCT04093349 - A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE) Phase 1/Phase 2
Completed NCT02363153 - Diet and Exercise in Pompe Disease N/A
Completed NCT00074932 - Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Late-onset Pompe Disease N/A
Completed NCT00025896 - Safety and Efficacy of Recombinant Human Acid Alpha-Glucosidase in the Treatment of Classical Infantile Pompe Disease Phase 2
Completed NCT00001331 - Genetic and Family Studies of Inherited Muscle Diseases N/A
Completed NCT00077662 - A Prospective, Observational Study in Patients With Late-Onset Pompe Disease N/A
Recruiting NCT05951790 - Inspiratory Muscle Training (IMT) in Adult People With Pompe Disease N/A
Completed NCT00125879 - Extension Study of Patients With Infantile-Onset Pompe Disease Who Were Previously Enrolled in Protocol AGLU01602 Phase 2/Phase 3
Recruiting NCT04848779 - A Prospective Study to Observe & Describe Clinical Outcomes of Alglucosidase Alfa Treatment in Patients ≤6 Months of Age With Infantile-onset Pompe Disease (IOPD)
Active, not recruiting NCT05164055 - Avalglucosidase Alfa French Post-trial Access for Participants With Pompe Disease (PTA Avalglucosidase) Phase 4
Recruiting NCT02761421 - Effect of Motor Development, Motor Function and Electrophysiologic Findings of IOPD Under ERT N/A
Completed NCT00051935 - A Study of the Safety and Pharmacokinetics of rhGAA in Siblings With Glycogen Storage Disease Type II Phase 2
Completed NCT00053573 - rhGAA in Patients With Infantile-onset Glycogen Storage Disease-II (Pompe Disease) Phase 1/Phase 2
Completed NCT02801539 - Respiratory Muscle Training in L-Onset Pompe Disease (LOPD) N/A
Completed NCT03687333 - Evaluate Efficacy and Safety in Chinese Patients With Infantile-Onset Pompe Disease With One Year Alglucosidase Alfa Treatment Phase 4